Johnson & Johnson CEO Joaquin Duato explains why the healthcare giant is skipping the obesity drug boom to focus on curing cancer and addressing dementia. He sat down with David Rubenstein. For more, watch Peer to Peer Conversations ▻
published
Johnson & Johnson CEO Joaquin Duato explains why the healthcare giant is skipping the obesity drug boom to focus on curing cancer and addressing dementia. He sat down with David Rubenstein. For more, watch Peer to Peer Conversations ▻
Open the original public source →
Latest documented BWB result
$NVDA market result
Exit $NVDA with $3 profit per share
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.